Beyfortus RSV Protection: Lancet Study Shows Lasting Infant Benefit
Beyond the First Season: How Advances in RSV Prevention are Reshaping Infant Healthcare Nearly 600,000 infants worldwide require hospitalization each year due to Respiratory Syncytial Virus (RSV), a figure that underscores the urgent need for effective preventative measures. But the recent data surrounding Beyfortus, a novel RSV preventative, suggests we’re entering a new era – … Read more